Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24195509)

  • 1. INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.
    An HJ; Choi EK; Kim JS; Hong SW; Moon JH; Shin JS; Ha SH; Kim KP; Hong YS; Lee JL; Choi EK; Lee JS; Jin DH; Kim TW
    Neoplasma; 2014; 61(1):56-62. PubMed ID: 24195509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
    Fridman JS; Scherle PA; Collins R; Burn T; Neilan CL; Hertel D; Contel N; Haley P; Thomas B; Shi J; Collier P; Rodgers JD; Shepard S; Metcalf B; Hollis G; Newton RC; Yeleswaram S; Friedman SM; Vaddi K
    J Invest Dermatol; 2011 Sep; 131(9):1838-44. PubMed ID: 21677670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
    Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
    Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
    de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
    Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
    Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
    Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells.
    Murata T; Noguchi PD; Puri RK
    J Biol Chem; 1995 Dec; 270(51):30829-36. PubMed ID: 8530527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.
    Punwani N; Scherle P; Flores R; Shi J; Liang J; Yeleswaram S; Levy R; Williams W; Gottlieb A
    J Am Acad Dermatol; 2012 Oct; 67(4):658-64. PubMed ID: 22281165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
    Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
    N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.
    Zhang Y; Liang R; Chen CW; Mallano T; Dees C; Distler A; Reich A; Bergmann C; Ramming A; Gelse K; Mielenz D; Distler O; Schett G; Distler JHW
    Ann Rheum Dis; 2017 Aug; 76(8):1467-1475. PubMed ID: 28478401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.
    Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J
    Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
    Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
    Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
    Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
    Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling.
    Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP
    Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
    Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
    J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor.
    Shimoda K; Feng J; Murakami H; Nagata S; Watling D; Rogers NC; Stark GR; Kerr IM; Ihle JN
    Blood; 1997 Jul; 90(2):597-604. PubMed ID: 9226159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
    Mascarenhas J
    Leuk Lymphoma; 2015; 56(9):2493-7. PubMed ID: 25586607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells.
    Agarwal C; Tyagi A; Kaur M; Agarwal R
    Carcinogenesis; 2007 Jul; 28(7):1463-70. PubMed ID: 17341659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
    Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
    Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.